Efficacy and Safety of Comprehensive Treatment in Patients with IR-CAD: a Self-controlled Cohort Study

RecruitingOBSERVATIONAL
Enrollment

39

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Coronary Artery DiseaseCoronary Artery StenosisCoronary Artery RestenosisCoronary Artery Disease ProgressionInflammationInflammatory DiseaseInflammation Vascular
Interventions
BEHAVIORAL

Healthy life style

Healthy diet, regular exercise, and quitting smoking

DRUG

Secondary prevention for atherosclerotic coronary artery disease

Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose

DRUG

Immunosuppressive therapy

Glucocorticoids and/or immunosuppressive agents

PROCEDURE

Coronary revascularization

Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).

DRUG

Supportive therapies

Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER